Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis
Even in non-obese individuals, GLP-1 medications can reduce systemic inflammation and improve insulin sensitivity, making them helpful for inflammatory or metabolic syndromes
All of the above analyses were performed using Stata software 13.0 (Stata Corp)
Cartier Esham, Ph.D., and Elizabeth Jungman
